MNTC Mentice AB (publ)
Mentice AB (publ), together with its subsidiaries, develops, sells, and markets solutions for training and decision support in the clinical area of interventional angiography in cardiology, neurology, vascular surgery, and radiology. It operates through the Mentice VIST, Physical Sim, and Ankyras segments. The company offers virtual simulation products, including VR simulator platforms; procedural learning models; peripheral vascular; patient simulator accessories and extensions for endovascular therapies; and Angiosuite integrations, such as the VIST virtual patient and Laerdal SimMan vascular medical simulator. It also provides flow model products, which include physiological flow systems, extensions and add-ons, silicone and 3D printed vessels, and flow system accessories; Ankyras, a clinical decision application; Mentice Live, a cloud-based learning center for medical technology industry and healthcare providers; Right Heart Cath app, a mobile solution for interactive real-time exploration into the right heart catheterization procedure; Vascular Twin, an anatomical replication for procedural and device adoption; research and development services; and professional support services for installation, training, and warranty services. It operates in Europe, the Middle East, Africa, the Asia Pacific, and the Americas. Mentice AB (publ) was founded in 1998 and is headquartered in Gothenburg, Sweden.…
Industry Peers
Medical DevicesKey Statistics
About Mentice (STO: MNTC)
›
Mentice (STO: MNTC) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 111 employees.
The shares were at 16.45 SEK on 19 November 2026, up 30.0% over 52 weeks. Its 52-week range is 12.00 SEK to 18.95 SEK: the price is 13.2% below the high and 37.1% above the low.
Its market capitalisation is 462.67M SEK.
Mentice reports return on equity of -23.4%, an operating margin of -7.2% and revenue up 2.9% year over year.
It holds more cash than debt, a net cash position of 45.00M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 2 analysts cover the stock, with an average rating of Buy; their mean price target of 23.00 SEK is 39.8% above the current price.